Molecularly targeted agents for renal cell carcinoma: the next generation.
With the approval of several molecularly targeted agents over the past few years, the landscape of renal cell carcinoma (RCC) management has drastically changed. Response rates and survival have improved with these new agents compared to the previous standard of cytokine-based therapy. Many new agents are in various stages of development, and how these novel therapies will be incorporated into the paradigm of RCC treatment is yet to be determined. The development of optimal sequencing and combinations of these drugs is important to improving patient outcomes and overcoming resistance mechanisms.
Cowey
C Lance
CL
Genitourinary Oncology and Melanoma Program, Baylor University Medical Center, Sammons Cancer Center, Dallas, TX 75246, USA. lance.cowey@usoncology.com
Hutson
Thomas E
TE
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D058570:TOR Serine-Threonine Kinases; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D047908:Intracellular Signaling Peptides and Proteins; D047428:Protein Kinase Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases